Welcome to our dedicated page for Perrigo Co Plc news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on Perrigo Co Plc stock.
Perrigo Company Plc (NYSE: PRGO) is a global provider of quality, affordable self-care products and over-the-counter health solutions. This dedicated news hub offers investors and industry professionals centralized access to official announcements, financial disclosures, and market developments.
Track Perrigo's strategic initiatives through verified press releases covering earnings results, product innovations, regulatory milestones, and partnership announcements. Our curated collection provides essential insights into the company's operations across key markets in North America, Europe, and global consumer health sectors.
Discover updates on Perrigo's store-brand leadership, branded OTC developments, and manufacturing advancements. The resource serves as a reliable reference for monitoring the company's progress in delivering accessible healthcare solutions through major retail partnerships and direct-to-consumer channels.
Bookmark this page for streamlined access to Perrigo's latest business updates, including analysis of market positioning in consumer self-care categories and operational efficiency programs. Stay informed about one of the OTC sector's most established innovators through verified, up-to-date information sources.
Perrigo Company plc (NYSE: PRGO) announced plans to release its first quarter 2023 financial results on May 9, 2023, accompanied by a conference call at 8:30 A.M. (EST). The conference call will be accessible via live webcast on Perrigo's investor relations website. A taped replay will be available from 12:00 P.M. (EST) on May 9 until midnight on May 16, 2023.
Perrigo focuses on Consumer Self-Care Products and over-the-counter health solutions, aiming to empower consumers in managing their health independently. The company warns that the earnings report may include forward-looking statements, which are subject to various risks and uncertainties.
Perrigo Company plc (NYSE: PRGO) announced a rescheduled FDA meeting set for May 9-10, 2023, to review their application for the Opill® daily oral contraceptive for over-the-counter (OTC) availability. If approved, Opill® would be the first OTC daily birth control pill in the U.S. This initiative is supported by key medical organizations advocating for increased access to contraception. The establishment of a dedicated Women's Health strategic organization reflects Perrigo's commitment to addressing women's health needs, aiming to empower individuals with affordable contraceptive options.
Perrigo Company plc (NYSE: PRGO) announced that its President and CEO, Murray S. Kessler, along with CFO Eduardo Bezerra, will present at the 12th Annual UBS Global Consumer and Retail Conference on March 15, 2023, at 3:00 PM EST in New York City. The presentation aims to discuss their consumer self-care products and OTC health solutions.
Interested parties can access the live presentation via the Perrigo website at http://perrigo.investorroom.com/events-webcasts. For more information on the company, visit www.perrigo.com.
